Breaking News, Financial News

Gilead Sciences 3Q

Gilead Sciences

3Q Revenues: $1.1 billion (+41%)

3Q Earnings: $398 million (net loss of $52 million in 3Q06)

YTD Revenues: $3.1 billion (+47%)

YTD Earnings: $1.2 billion (+155%)

Comments: Sales of new HIV medication Atripla reached $241 million, after posting $68 million in 3Q06. Sales of top product Truvada increased 30% to $409 million. Overall, the HIV franchise was up 45% to $806 million, while non-HIV products Hepsera (hepatitis B) and Ambisome (severe fungal infection) contributed $148 million to 3Q revenues, up from $110 million in 3Q06.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters